Initial treatment of cancer patients with fluconazole-susceptible dose-dependent Candida glabrata fungemia: Better outcome with an echinocandin or polyene compared to an azole?

Audrey Le; Dimitrios Farmakiotis; Jeffrey J. Tarrand; Dimitrios P. Kontoyiannis

doi:10.1128/AAC.00631-17

Initial treatment of cancer patients with fluconazole-susceptible dose-dependent Candida glabrata fungemia: Better outcome with an echinocandin or polyene compared to an azole?

Audrey Le, Dimitrios Farmakiotis, Jeffrey J. Tarrand, Dimitrios P. Kontoyiannis

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

The 28-day crude mortality rate in 68 cancer patients with fluconazole-susceptible dose-dependent Candida glabrata fungemia started on treatment (within 48 h after blood culture collection) with an echinocandin or liposomal amphotericin-B was better (30%) than those treated with azole monotherapy (52%) (P = 0.07). After adjusting for confounders, azole monotherapy also was associated with worse 28-day survival (hazard ratio, 3.8; P = 0.003).

Original language	English (US)
Article number	e00631
Journal	Antimicrobial agents and chemotherapy
Volume	61
Issue number	8
DOIs	https://doi.org/10.1128/AAC.00631-17
State	Published - Aug 2017

Keywords

Azole monotherapy
Candida glabrata
Candidemia
Echinocandin
Polyenes

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.00631-17

Cite this

Initial treatment of cancer patients with fluconazole-susceptible dose-dependent Candida glabrata fungemia: Better outcome with an echinocandin or polyene compared to an azole? / Le, Audrey; Farmakiotis, Dimitrios; Tarrand, Jeffrey J. et al.
In: Antimicrobial agents and chemotherapy, Vol. 61, No. 8, e00631, 08.2017.

Research output: Contribution to journal › Article › peer-review

@article{89132691439548188848ecd0c5e0f653,

title = "Initial treatment of cancer patients with fluconazole-susceptible dose-dependent Candida glabrata fungemia: Better outcome with an echinocandin or polyene compared to an azole?",

abstract = "The 28-day crude mortality rate in 68 cancer patients with fluconazole-susceptible dose-dependent Candida glabrata fungemia started on treatment (within 48 h after blood culture collection) with an echinocandin or liposomal amphotericin-B was better (30%) than those treated with azole monotherapy (52%) (P = 0.07). After adjusting for confounders, azole monotherapy also was associated with worse 28-day survival (hazard ratio, 3.8; P = 0.003).",

keywords = "Azole monotherapy, Candida glabrata, Candidemia, Echinocandin, Polyenes",

author = "Audrey Le and Dimitrios Farmakiotis and Tarrand, {Jeffrey J.} and Kontoyiannis, {Dimitrios P.}",

year = "2017",

month = aug,

doi = "10.1128/AAC.00631-17",

language = "English (US)",

volume = "61",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "8",

}

TY - JOUR

T1 - Initial treatment of cancer patients with fluconazole-susceptible dose-dependent Candida glabrata fungemia

T2 - Better outcome with an echinocandin or polyene compared to an azole?

AU - Le, Audrey

AU - Farmakiotis, Dimitrios

AU - Tarrand, Jeffrey J.

AU - Kontoyiannis, Dimitrios P.

PY - 2017/8

Y1 - 2017/8

N2 - The 28-day crude mortality rate in 68 cancer patients with fluconazole-susceptible dose-dependent Candida glabrata fungemia started on treatment (within 48 h after blood culture collection) with an echinocandin or liposomal amphotericin-B was better (30%) than those treated with azole monotherapy (52%) (P = 0.07). After adjusting for confounders, azole monotherapy also was associated with worse 28-day survival (hazard ratio, 3.8; P = 0.003).

AB - The 28-day crude mortality rate in 68 cancer patients with fluconazole-susceptible dose-dependent Candida glabrata fungemia started on treatment (within 48 h after blood culture collection) with an echinocandin or liposomal amphotericin-B was better (30%) than those treated with azole monotherapy (52%) (P = 0.07). After adjusting for confounders, azole monotherapy also was associated with worse 28-day survival (hazard ratio, 3.8; P = 0.003).

KW - Azole monotherapy

KW - Candida glabrata

KW - Candidemia

KW - Echinocandin

KW - Polyenes

UR - http://www.scopus.com/inward/record.url?scp=85026353196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026353196&partnerID=8YFLogxK

U2 - 10.1128/AAC.00631-17

DO - 10.1128/AAC.00631-17

M3 - Article

C2 - 28584138

AN - SCOPUS:85026353196

SN - 0066-4804

VL - 61

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 8

M1 - e00631

ER -